Innovative Hybrid Designs and Analytical Approaches Leveraging Real-World Data and Clinical Trial Data | SpringerLink
Active-comparator arm - RaDaR
Controls, comparator arms, and designs for critical care comparative effectiveness research: It's complicated - Verity J Ford, Harvey G Klein, Robert L Danner, Willard N Applefeld, Jeffrey Wang, Irene Cortes-Puch, Peter Q
![PDF] Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/59e6f477143222b0341e0568c8f08b26f2d8dc27/5-Figure1-1.png "PDF] Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study | Semantic Scholar")
PDF] Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study | Semantic Scholar
PRS Performance Support Tool
On Biostatistics and Clinical Trials: Synthetic Control Arm (SCA), External Control, Historical Control
NCT02257567 (Clinical Trial / Polatuzumab Vedotin / DCDS4501A / RG-7596) | ADC Review
Clinical trial designs of new medicinal products for treating schizophrenia: discussion of EMA's Guideline and a Better Long Term Trial Design
Most noninferiority trials were not designed to preserve active comparator treatment effects - ScienceDirect
Securing market access with single-arm trial data - IQVIA
Synthetic control arms are a good option for some clinical trials - STAT
White Paper title goes here
Clinical trial designs of new medicinal products for treating schizophrenia: discussion of EMA's Guideline and a Better Long Term Trial Design
Securing market access with single-arm trial data - IQVIA
Active-comparator design and new-user design in observational studies. - Abstract - Europe PMC
New‐user and prevalent‐user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting p
Clinical trial designs of new medicinal products for treating schizophrenia: discussion of EMA's Guideline and a Better Long Term Trial Design
Controls, comparator arms, and designs for critical care comparative effectiveness research: It's complicated - Verity J Ford, Harvey G Klein, Robert L Danner, Willard N Applefeld, Jeffrey Wang, Irene Cortes-Puch, Peter Q
Clinical trial overview. CT Computed tomography, CT group Active... | Download Scientific Diagram
Leveraging external data in the design and analysis of clinical trials in neuro-oncology - The Lancet Oncology
Assessment of non-inferiority with meta-analysis: example of hypofractionated radiation therapy in breast and prostate cancer | Scientific Reports
New‐user and prevalent‐user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices - Luijken - 2021 - Pharmacoepidemiology and Drug Safety - Wiley Online Library
Clinical trial designs of new medicinal products for treating schizophrenia: discussion of EMA's Guideline and a Better Long Term Trial Design
Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials | Journal of the American College of Cardiology
Transforming Clinical Trials with Real-World Evidence | BCG
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis - eBioMedicine
Genelux Corporation | Our Program
